Professor, CLL/Lymphoma. Targeted therapy , CAR-T & BsAbs. Deputy Chief Medical Officer, Medical Director,Cellular Immunotherapy, Fred Hutch and U of Washington

Joined March 2009
157 Photos and videos
Pinned Tweet
Excited to kick-off the @SWOG S2504 trial which is the first randomized trial for Richter Transformation (RT) in the US: Pirtobrutinib with RCHOP vs. RCHOP is TN RT Asking all #CLL and #lymphoma experts to participate and spread the word. Special thanks to @DebbieMStephens the study co-chair and @DanilovLab the TM chair. Thanks to @NCIMedia and @EliLillyandCo @CllSociety @lymphoma @SOU_LnL_Fund @fredhutch @cityofhope @UNC_Lineberger
1
4
17
1,753
Mazyar Shadman, MD MPH retweeted
CONGRESS | #EHA2026 | POSTER Mazyar Shadman presents the 7-year follow-up data from Arms A and B of the phase III SEQUOIA study evaluating follow-up therapies after zanubrutinib vs bendamustine-rituximab (BR) in treatment-naive patients with CLL or SLL (N = 479). Zanubrutinib showed sustained PFS superiority vs BR (HR 0.28; p < 0.001) with a 78-month PFS rate of 71.8% vs 31.0%. Zanubrutinib showed prolonged TTNT (HR 0.24; p < 0.001) and TTNT-D (HR 0.37; p < 0.0001). PFS2 remained superior with zanubrutinib vs BR (HR 0.70); responses to subsequent BCL2i‑based therapy were favorable with zanubrutinib. The findings support the use of zanubrutinib as a frontline treatment option for CLL while maintaining responses to subsequent therapies. Follow our live feed for more updates: loom.ly/ilKkUIM Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. a full list of supporters can be found on our website. #leusm #lymsm #MedicalCongress @mshadman @fredhutch
6
13
1,038
Mazyar Shadman, MD MPH retweeted
My thoughts on new data from EHA. When considered in context of other recently published studies, these results should definitively end the practice of high-dose methotrexate prophylaxis in DLBCL. @JCO_ASCO ascopubs.org/doi/10.1200/JCO…
2
15
42
6,747
Mazyar Shadman, MD MPH retweeted
CONGRESS | #ASCO26 | POSTER Mazyar Shadman shares updated safety and efficacy results from a phase I/Ib BGB-11417-101 trial of sonrotoclax (160 mg, n = 51; 320 mg, n = 86) zanubrutinib in patients with treatment-naïve CLL (n = 137). In the efficacy-evaluable patients (n = 135), the ORR was 100%, with a CR rate of 51.0% and 59.5% in the 160 mg and 320 mg cohorts, respectively. At a median follow-up of 30.7 months, no progression was observed in the 320 mg cohort. In the 320 mg cohort, best blood uMRD5 rate as measured by NGS was 87.3%. The most common any grade TEAEs were neutropenia (43.1%), COVID-19 (40.1%), contusion/bruising (38.7%), and diarrhea (32.1%). Sonrotoclax zanubrutinib is currently being evaluated in patients with treatment-naïve CLL in two phase III trials. Follow our live feed for more updates: bit.ly/3PJhHqD Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #leusm #lymsm #MedicalCongress @mshadman @fredhutch
2
5
647
Mazyar Shadman, MD MPH retweeted
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26
92
1,273
6,505
1,148,701
Powerful speech by Dr. Eric Small @ASCOPres @ASCO president. Reminding our mission: every patient, every cancer, everywhere. @fredhutch #ASCO26
1
6
273
Invaluable advice!
How are clinical trial leaders picked? No one can or will hand you a principal investigator role on a platter. You have to work for it. Some things you can do if you are interested in leading a clinical trial. 1) Become a disease expert. Really understand the disease well. When you speak or write colleagues should recognize your talent and depth. The more you speak and write the more you will be noticed and sought out. Social media helps raise your visibility but it has no value if others think you are superficial. You must be credible. This is the most important step. There are no short cuts except to really understand the disease, what is known, and what remains to be known. It’s hard work. 2) Volunteer to be co-investigators on trials and help with trial design, development, and accrual. 3) Network. Most senior investigators will be more than happy to help you succeed. 4) Study trial protocols in depth to understand the elements and how it’s formatted. Better still write out protocol concepts and protocols. Clinical trial workshops help. There is an awful lot of detail. 5) Identify important questions that others are not thinking of. The question should be original, authentic, and important. If you have a great question, and you are credible, you are on your way to leading a trial. (The process from that point on is still very long and arduous — see second tweet in thread. But you have made it to being the PI). Clinical trial leadership is not transferable. When you are asked to be a lead investigator it’s not in your power to hand it over. If you don’t want it, that spot will go to the next most credible person not the one you anoint. As it should be.
5
3,445
Excited to kick off our inaugural “Fred Hutch and Friends” meeting! Outstanding participation from both academic and community oncology practices. This year’s theme is Immunotherapy, with the goal of bringing academic and community partners together to advance collaboration, education, and patient care. @fredhutch #FredHutchandFriends @gotoPER @PGrivasMDPhD
3
11
1,600
Appreciation to @DrJFriedberg as he steps down as Chair of the @SWOG Lymphoma Committee. His leadership, mentorship, and vision have had a lasting impact on the committee and the field. We’ve learned a great deal from him—he truly led by example over the past 10 years. I’ve been fortunate to be part of this group during that time and look forward to working with @SoniSmithMD as she steps into this role and continues to move the field forward.
1
4
29
1,225
Mazyar Shadman, MD MPH retweeted
Passed the ⁦@SWOG⁩ lymphoma committee gavel to friend and colleague Dr Sonali Smith today. The committee is in fantastic hands.
10
11
93
4,667
Mazyar Shadman, MD MPH retweeted
OncLive is proud to share that the 2025 #BTGhem Lymphoma Consensus Manuscript is now published in Cancer! Our expert faculty used a modified Delphi process to develop consensus recommendations across MCL, CLL, and DLBCL, addressing risk stratification, novel agent sequencing, and the evolving role of CAR-T cell therapy. Read the full article: hubs.li/Q04dDmcj0 #BTGHEM #Lymphoma #HemOnc #MCL #CLL #DLBCL @LymphClinician @jonathonbcohen @BrianHill_MDPhD @KrishPatelMD @drjoannarhodes1 @YucaiWangMD @mshadman
4
7
636
CELESTIAL-2 is official. Will present the TIP abstract at #ASCO26 Zanubrutinib plus Sonrotoclax (ZS) vs. Acalabrutinib plus Venetoclax for TN #CLL What will be the best all oral FD treatment for CLL? asco.org/abstracts-presentat… @fredhutch

1
5
26
2,816
Mazyar Shadman, MD MPH retweeted
AZD5492. CLL/NHL. A new wave of T-cell engagers 🧬 @mshadman is live at #iwCART26! Stay tuned for the highlights! #CellTherapy #Oncology #Immunotherapy
3
5
522
Mazyar Shadman, MD MPH retweeted
Join us for Immune Therapies in Practice 2026, a one‑day conference from Fred Hutch & @gotoPER! Explore how next‑gen immune therapies are reshaping care across hematologic and solid tumors. Co-Chairs: @PGrivasMDPhD & @mshadman. Register: bit.ly/4qSt6kt
2
12
849
Mazyar Shadman, MD MPH retweeted
At Fred Hutch, breakthroughs don’t stop in the lab. Decades of research showing how the immune system can eradicate cancer have led to FDA‑approved #CARTcelltherapies that are now standard treatments for patients with blood cancers and beyond. @mshadman 🎧 bit.ly/4sRVtkr
3
8
820
Mazyar Shadman, MD MPH retweeted
Join us for Immune Therapies in Practice 2026, a one‑day conference from Fred Hutch & @gotoPER! Explore how next‑gen immune therapies are reshaping care across hematologic and solid tumors. Co-Chairs: @PGrivasMDPhD & @mshadman. Register: bit.ly/4qSt6kt
1
5
2,407
Mazyar Shadman, MD MPH retweeted
Replying to @theNCI
In 1L cHL Stg III or IV, #Nivolumab AVD is now ✅ @US_FDA approved based off @SWOG 1826 (vs. #Brentuximab AVD): - mPFS not reached. PFS HR: 0.42 - ⬆️ neuropathy & discontinuation w/ Bv-AVD - Adopted in clinical practice since its presentation. Now SoC #lysm #HemeTwitter
5
14
2,421
Mazyar Shadman, MD MPH retweeted
Wonderful news! A testment to the great work on @SWOG S1826 lead by Dr Herrera and @DrJFriedberg!
Finalllllly 👍
2
16
1,111